Achilles Therapeutics plc
ACHL
$1.48
$0.010.68%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.43% | 0.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.71% | 24.48% | |||
| Operating Income | -14.71% | -24.48% | |||
| Income Before Tax | -19.72% | -33.14% | |||
| Income Tax Expenses | -162.50% | 134.78% | |||
| Earnings from Continuing Operations | -19.63% | -33.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.63% | -33.45% | |||
| EBIT | -14.71% | -24.48% | |||
| EBITDA | -15.62% | -26.70% | |||
| EPS Basic | -19.41% | -33.21% | |||
| Normalized Basic EPS | -19.48% | -32.91% | |||
| EPS Diluted | -19.41% | -33.21% | |||
| Normalized Diluted EPS | -19.48% | -32.91% | |||
| Average Basic Shares Outstanding | 0.18% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
